Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019
Publication date Mar 2019
Publisher Current Partnering
Number of pages 1,000+
Report edition 3
Product code CP2057
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest preclinical agreements announced in the healthcare sector.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

 

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

 

Chapter 5 provides a review of preclinical stage deal making since 2014. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

 

Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.

 

Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

 

Chapter 8 provides a comprehensive listing of the top 50 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

 

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.

 

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2014.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2014.

 

In addition, a comprehensive appendix of all preclinical deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

 

Key benefits

 

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 provides the reader with the following key benefits:

 

  • In-depth understanding of preclinical stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of preclinical stage agreements with numerous real life case studies
  • Insight into the terms included in a preclinical stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.

 

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 includes:

 

  • Trends in preclinical stage dealmaking in the biopharma industry since 2014
  • Analysis of preclinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life preclinical stage deals
  • Access to over 2,000 preclinical stage deals
  • The leading preclinical stage deals by value since 2014
  • Most active preclinical stage dealmakers since 2014
  • The leading preclinical stage partnering resources

 

In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides comprehensive access to available deals and contract documents for over 2,000 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides the reader with the following key benefits:

 

  • In-depth understanding of preclinical stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
  • Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of preclinical stage agreements with numerous real life case studies
  • Identify leading preclinical stage deals by value since 2014
  • Identify the most active preclinical stage dealmakers since 2014
  • Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Why do companies partner preclinical stage compounds?           

 

2.1. Introduction

2.2. The role of preclinical stage partnering

2.2.1. In-licensing at preclinical stage

2.2.2. Out-licensing at preclinical stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into preclinical stage partnering deals

2.4.1. Licensors reasons for entering preclinical stage deals

2.4.2. Licensees reasons for entering preclinical stage deals

2.5. The future of preclinical stage partnering deals

 

Chapter 3 – Preclinical stage deal strategies and structure

 

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical / biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study: LEO Pharma - 4SC

3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

3.2.1.1.c. Case study: Incyte – Agenus Bio

3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study: Servier – GeNeuro

3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

3.2.2.1.c. Case study: AstraZeneca - Ardelyx

3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on preclinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure preclinical stage licensing agreements

3.6.1.a. Case study : Merck and Co. – Tesaro

3.6.1.b. Case study : Marina Biotech – Mirna Therapeutics

3.7. Multicomponent preclinical stage partnering agreements

3.7.1. Example multicomponent preclinical stage clauses

3.7.1.a. Case study: Eleven Biotherapeutics – ThromboGenics

3.7.1.b. Case study: Pfizer – InSite Vision

 

Chapter 4 – Preclinical stage partnering payment strategies

 

4.1. Introduction

4.2. Preclinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

 

Chapter 5 – Trends in preclinical stage deal making

 

5.1. Introduction

5.2. Preclinical stage partnering over the years

5.2.1. Attributes of preclinical deals

5.3. Preclinical stage partnering by deal type

5.4. Preclinical stage partnering by disease type

5.5. Partnering by preclinical stage technology type

5.6. Preclinical stage partnering by most active company since 2014

 

Chapter 6 – Payment terms for preclinical stage partnering

 

6.1. Introduction

6.2. Guidelines for preclinical stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Preclinical stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Preclinical stage headline values

6.4.2. Preclinical stage deal upfront payments

6.4.3. Preclinical stage deal milestone payments

6.4.4. Preclinical stage royalty rates

 

Chapter 7 – Leading preclinical stage deals

 

7.1. Introduction

7.2. Top preclinical stage deals by value

 

Chapter 8 – Top 50 most active preclinical stage dealmakers

 

8.1. Introduction

8.2. Top 50 most active preclinical stage dealmakers

 

Chapter 9 – Preclinical stage partnering contracts directory

 

9.1. Introduction

9.2. Preclinical stage deals with contracts 2014 to 2019

 

Chapter 10 – Preclinical stage deal making by development stage

 

10.1. Introduction

10.2. Deals by preclinical stage

 

Appendices

 

Appendix 1 – Preclinical stage dealmaking by companies A-Z

Appendix 2 – Preclinical stage dealmaking by industry sector

Appendix 3 – Preclinical stage dealmaking by stage of development

Appendix 4 – Preclinical stage dealmaking by therapy area

Appendix 5 – Preclinical stage dealmaking by technology type

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent titles from Current Partnering

 

Table of figures

 

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

Figure 2: Agreements signed by phase of development (2014- 2019), % of all deals

Figure 3: Components of the pure licensing deal structure

Figure 4: Payment options for preclinical stage partnering deals

Figure 5: Issues affecting royalty rates

Figure 6: Preclinical stage partnering frequency since 2014

Figure 7: Preclinical stage partnering by deal type since 2014

Figure 8: Preclinical stage partnering by disease type since 2014

Figure 9: Preclinical stage partnering by technology type since 2014

Figure 10: Top 50 most active preclinical stage dealmakers since 2014

Figure 11: Review of upfront payments for preclinical stage deals

Figure 12: Review of milestone payments for preclinical stage deals

Figure 13: Review of royalty payments for preclinical stage deals

Figure 14: Preclinical stage deals with a headline value

Figure 15: Preclinical stage deals with an upfront value

Figure 16: Preclinical stage deals with a milestone value

Figure 17: Preclinical stage deals with a royalty rate value

Figure 18: Top preclinical stage deals by value since 2014

Figure 19: Most active preclinical stage dealmakers since 2014

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2019 Wildwood Ventures Ltd.